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Abstract
Background: In a previous study (Goebel et. al, Cancer Genomics Proteomics 16:229-244, 2019), we identified 33
biomarkers for an early stage (I-II) Non-Small Cell Lung Cancer (NSCLC) test with 90% accuracy, 80.3% sensitivity,
and 95.4% specificity. For the current study, we used a narrowed ensemble of 21 biomarkers while retaining similar
accuracy in detecting early stage lung cancer.
Methods: A multiplex platform, 486 human plasma samples, and 21 biomarkers were used to develop and validate
our algorithm which detects early stage NSCLC. The training set consisted of 258 human plasma with 79 Stage I-II
NSCLC samples. The 21 biomarkers with the statistical model (Lung Cancer Detector Test 1, LCDT1) was then
validated using 228 novel samples which included 55 Stage I NSCLC.
Results: The LCDT1 exhibited 95.6% accuracy, 89.1% sensitivity, and 97.7% specificity in detecting Stage I NSCLC on
the blind set. When only NSCLC cancers were analyzed, the specificity increased to 99.1%.
Conclusions: Compared to current approved clinical methods for diagnosing NSCLC, the LCDT1 greatly improves
accuracy while being non-invasive; a simple, cost-effective, early diagnostic blood test should result in expanding
access and increase survival rate.
Keywords: Immunoassay, Early stage lung cancer, Detection, Biomarkers, Proteomics, Diagnostic tests, Non-small
cell lung cancer

Background
Lung cancer is a pervasive disease that is commonly diagnosed at a late stage and has a global estimated mortality rate of 84.2% for 2019. The American Cancer
Society predicts about 228,150 new cases and 142,670
deaths for 2019 in the United States. On average, 422
Americans die every day of lung cancer (LC). Non-small
Cell Lung Cancer (NSCLC) accounts for 84% of all LCs,
and exhibits a 5-year survival rate of 23% [1]. However,
if NSCLC is detected at stages I-II, the survival rate significantly improves and it may even be cured [2].
NSCLC patients diagnosed at stage I have a 5-year survival rate between 68 and 92%; at stage II between 53
* Correspondence: cherylleg@lcproteomics.com
1
Goebel Consulting Inc., Mountain View, 780 Montague Expressway, Suite
703, San Jose, CA 95131, USA
Full list of author information is available at the end of the article

and 60%; at stage III, it decreases to 26–36%; and for
stage IV detection the survival rate drops precipitously
to 1–10% [1, 2]. Despite significant investment and advancement in LC research, only 16% of LCs are detected
at the early stages [1].
The research community continues to improve early
LC detection through the use of Computed Tomography
(CT) and Positron Emission Tomography (PET) scans,
improved pulmonary nodule (PN) guideline, biomarkers,
and machine learning algorithms. In our approach, we
combine biomarkers and machine learning. We detect
early stage NSCLC with high sensitivity and specificity
using a simple blood test. Before presenting our results,
we briefly review the state-of-the-art of these
approaches.

© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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CT scans recommended for diagnosing LC

The US Preventive Service Task Force (USPSTF) recommends that low-dose computed tomography (LDCT)
scans be used as a screening method for LC in high risk
patients age 55–85 with a 30-year smoking history, who
have not quit for more than 15 years. The recommendation was in part based on the National Lung Screening
Trial (NLST) study which demonstrated that screening
with LDCT reduces LC mortality by 20% compared to
chest x-rays [3, 4]. However, this approach is not ideal.
In the NLST study, a PN was detected in 1 of every 4
subjects that had LDCT scans. Of the 7191 subjects
found to have suspicious nodules on LDCT scans, 88.6%
had a follow-up test (e.g., imaging, 89.8%; biopsy, 1.9%;
and surgery, 4.7%), and only 292 (4.1%) were confirmed
to have LC. Of these 292 cases, 54.1 and 41.1%, turned
out to be Stage I and II, respectively. The LDCT scans
had a false positive rate (FPR) of 96.1% [4]. Obviously,
there is a need for a test with a lower FPR. Deep learning
algorithms show promise to reduce the false positives in
interpreting these images [5].
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adherence to new guidelines and outcome on performed
PN follow-up procedures will need to be completed.
Evaluating biomarkers to detect LC

There is a growing trend to use genetic and protein biomarkers for disease diagnosis, prognosis, and the evaluation of treatment efficacy (e.g., Grail, Guardant, Myriad
Genetics) [11, 12]. Biomarkers are defined as ‘any substance, structure, or process that can be measured in the
body or its products and influence or predict outcome or
disease’ [13]. Thus, a biomarker can be of physical,
chemical, or biological nature, such as measurements of
blood pressure, temperature, inflammatory cytokines
(proteins), genetic (DNA) markers, or metabolites [14].
In this paper, we will limit our discussion to DNA and
protein biomarkers.
DNA biomarkers

PET scans have better statistics than LDCT [6]. A multicenter observational study by Tanner, et al., [7] evaluating PN management shows an increase in PET scan use
with additional follow-ups of patients with indeterminate
lung nodules. The accuracy rate of PET scans is 74%,
with an overall FPR of 39% (36–55%) and overall false
negative rate (FNR) of 9% (8–10%), depending on node
size. The study concludes that 25% of PNs referred to a
pulmonologist were malignant; 46% had additional surveillance, 33.2% had a biopsy, and 20.4% underwent lung
surgery. About 35% of patients who had surgery had benign masses.

DNA biomarkers have been used to assess risk for developing specific diseases or response to therapy. DNA provides genetic information of the individual. Nonetheless,
the path from DNA to an observable physical trait (e.g.,
disease) is complex. For instance, somatic mutations in
the TP53, EGFR, and KRAS genes are commonly found
in LC patients [15]; yet, somatic mutations are often due
to increased exposure to carcinogens (e.g., smoking,
radon), environmental factors (e.g., pollution, secondhand smoke), age, and health history (e.g., chronic
COPD). Inherited mutations following an autosomal
dominant pattern predispose an individual to be at high
risk, but need not always predict the development of LC.
The pattern of inheritance, penetrance, and expressivity
of genetic mutations, in addition to lifestyle, environmental factors, and even ethnicity, are important components in assessing cancer risk [16].

Pulmonary nodule guidelines

Protein biomarkers

Most solitary PNs are detected incidentally by chest radiography and CT scans that were ordered to investigate
other diseases. Approximately 150,000 solitary PNs are detected annually in the United States of America [8].
Recommendations for managing intermediate PNs,
found in PET/CTs using the Lung-RADS [7, 9] or
Fleischner criteria [10], are not always followed. Many
physicians consider other factors, such as age, smoking
status, gender, patient preference, and use their experience when deciding on follow-up procedures for that patient’s specific clinical situation. In a multicenter
observational study of 377 patients, Tanner et al., indicated that invasive procedures were performed in 44% of
low risk nodules (< 5% probability of malignancy) [7].
Today, current guidelines for management of lung nodules try to incorporate other factors that may be unique
to a patient [9, 10]. Prospective research on physician

In contrast, protein reflects phenotype: the observable
end-trait (e.g., tissue) resulting from the interaction of
genome and the environment [17]. Protein biomarkers
provide quantitative data that can be compared between a healthy and a diseased individual. Proteomics
has its own challenges. Proteins, like genes, are pleiotropic: meaning the same protein markers may contribute to different immune-related pathways for
different diseases. For example, IL-8 is a pleiotropic
cytokine and has also been linked to breast, prostate,
lung, colorectal, and skin cancer [18]. Hence, using a
single biomarker, protein or DNA, would not be sufficient for clinical diagnostic use.
Protein levels can fluctuate due to physiological
stressors (e.g., disease, strenuous exercise) and samples
(i.e., serum, plasma) are sensitive to environmental factors
(i.e., pH, temperature) and degrade faster than DNA.

PET scans increasing in use for LC follow-ups
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Moreover, analytic protein platforms require the use of
antibodies which, in turn, exhibit lot-to-lot variations due
to the idiosyncratic nature of antibodies.
Despite the intricacies, genome and protein biomarkers, have proven to be essential tools in the discovery of predictive, prognostic, and diagnostic markers in
LC [19–21].
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Methods
This study is a continuation of our previous research
that used 33 biomarkers [11]. Here we reduced the number of biomarkers to 21, ensured successful transfer of
reagents, and retrained our algorithm.

Study population
Machine learning in medicine

Advances in computing combined with an increase in
the amount of data collected has enabled the application
of various machine learning techniques, such as Neural
Networks and Random Forests, to tease out complex
and non-linear relationships in data. These methods can
also assist radiologists to interpret x-rays, CAT scans,
PET scans and other diagnostic imaging methods; diagnose patients with disease; and may lead to a general improvement in patient care [22].
While machine learning methods are powerful, they
have drawbacks. No machine learning method can compensate for poor data (i.e., dirty data). Machine learning
is unable to provide causal information on its own; they
are simply a set of advanced statistical techniques that
can improve our ability to find complex, non-linear relationships in data [23, 24].
Further, statistical models can be impacted by bias,
human error, sample population, poor technical design, misapplication, and disparate systems. It is important that appropriate machine learning techniques
and algorithms are applied to each study, that the data
is collected, cleaned and processed in a consistent
manner, and that bias are scrutinized from all angles
[25].
Our preliminary studies identified protein biomarkers
that may significantly improve our ability to identify
NSCLC so this study was undertaken to prospectively
test that hypothesis.

This study was performed on biobank plasma samples
from 486 subjects distributed into 5 cohorts (Table 1).
In previous studies, we demonstrated that our method
detected early to late stage NSCLC. In this study, our
focus was to detect stage I-II LC. Therefore, samples
from patients with Stage I-II NSCLC (Table 2) were
used to train the LCDT1 algorithm and, subsequently,
only Stage I NSCLC samples (Table 2) were used in a
blind set to validate clinical efficacy.

Sample collection and handling

Human plasma samples were obtained from five blood
banks: Asterand, BioReclamation, BioSource, Geneticist,
and Proteogenex. All cancer samples were confirmed by
histology. All samples were collected through an IRB approved protocol (e.g., Protocol #AST-FPB-003, Western
IRB) or a signed Waiver of Consent form. Individuals
under the age of 18 or those who cannot consent for
themselves were not included in the study. Samples were
collected in the United States between 2013 and 2015.
Clinical information such as age, gender, pathology
and stage, race, origin, smoking status, and sample collection dates were obtained. Whole blood samples were
collected in EDTA tubes and stored at − 80 °C according
to the biobank’s protocol. Plasma samples were transported on dry ice overnight to our sample storage site in
Michigan City, Indiana, USA. Vials were inspected visually for damage upon receipt and stored at − 80 °C until
analysis.

Table 1 Sample Criteria
Cohort

Inclusion

Exclusion

All cohort

M/F, 18 y/o or older, sample collected in the USA

Pregnant, incarcerated, lack of capacity to consent, samples collected
outside of sthe United States

Asthma

Smoker or non-smoker

Any cancer diagnosis

Non-Smoker Healthy

Smokers, any cancer diagnosis

NSCLC,
(Stage I-II)

Stage I-II; smoker or non-smoker

Stage III-IV lung cancer

Smoker

10 pack years

Any cancer diagnosis

Other
Cancers

Breast, colon-rectal, pancreatic, and prostate cancer, all stages;
smoker or non-smoker

The non-smoker and NSCLC served as negative and positive control for lung cancer, respectively. Asthma sufferer and COPDs were included to test whether the
diagnostic test can differentiate lung cancer from those who may have other respiratory diseases which share similar symptoms. The smokers consisted of highrisk population for LC who were not diagnosed with any cancer. Other cancers (i.e., breast, prostate, pancreatic, and colon-rectal) were included to ensure that the
diagnostic test was specific to NSCLC
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Table 2 Sample Distribution
African-American Caucasian Hispanic Total
Training Set
Female

37

69

27

133

Asthma

0

10

1

11

Breast Cancer

0

1

0

1

Colon-Rectal Cancer 0

2

0

2

Non-Smoker

17

10

42

15

NSCLC, (Stage I-II)

10

22

10

42

Pancreatic Cancer

0

2

0

2

Smoker

12

15

6

33

49

53

23

126

Asthma

0

4

0

4

Non-Smoker

18

14

9

41

Male

NSCLC, (Stage I-II)

9

17

10

37

Pancreatic Cancer

0

2

0

2

Smoker

22

16

4

42

86

122

50

258

29

88

18

135

Total
Validation Set
Female
Asthma

0

8

0

8

Breast Cancer

5

35

0

40

Colon-Rectal Cancer 0

3

0

3

Non-Smoker

12

9

30

9

in the previous study [11] to ensure that all biomarkers
performed similarly and maintained its congruity with
the algorithm.
Algorithm and statistical analysis

The algorithm considers duplicate measurements of the
biomarkers from a patient and classifies each measurement as having NSCLC or not having NSCLC. If any of
the measurement is classified as being from a subject
with NSCLC, the subject is classified as having NSCLC.
Since the implicit costs of allowing the disease to progress without treatment is greater than the cost of a false
negative, the LCDT1 algorithm errs on the side of predicting that a subject has NSCLC.
A 5-PL curve was used to acquire the calibration
curve. Data was cleaned based on preset criteria of ±20%
coefficient of variation and removal of extrapolated and
out of range data. Median, rather than average, was used
to represent the central tendency of the plasma concentrations due to the skewed distributions and outliers.
Normalization of diseased cohorts to healthy cohorts
was examined for pattern recognition. P-values were calculated using T-tests, adjusted using BenjaminiHochberg’s method for multiple comparisons [26]. The
AUC was calculated for each biomarker and as a combined set of biomarkers. The ROC curve was used illustrate the performance of the model. Excel and R Version
3.4.4 were used for data analysis.

NSCLC, Stage I

6

17

4

27

Pancreatic Cancer

0

2

0

2

Results

Smoker

9

11

5

25

Training set for optimizing the LCDT1 algorithm

25

51

17

93

Male
Asthma

0

3

0

3

Colon-Rectal Cancer 0

2

0

2

Non-Smoker

7

11

9

27

NSCLC, Stage I

5

18

5

28

Pancreatic Cancer

0

1

0

1

Prostate

3

6

0

9

Smoker

10

10

3

23

54

139

35

228

Total

All samples were collected in the United States and proportionately
distributed between genders. The age range was between 21 and 82 years old
with an average age of 56

Multiplexed immunoassay procedure

This study used a custom-made multiplexed immunoassay to measure the concentration of 21 biomarkers in
human plasma samples. Sample collection and handling,
and immunoassay procedure are consistent with our
previous study (1, Supplementary Figure 1). Sample processing was performed by Eve Technologies Corporation
(Calgary, Alberta, Canada). This assay reagent and format was validated against the 33-biomarker reagent used

In this study, we included the 33-biomarker model to
examine congruity in using a higher set of biomarkers
versus a smaller subset. Table 3 illustrates the algorithm
performance using 33 versus 21 biomarkers are analogous. The LCDT1 algorithm was developed with slight
modifications using a smaller subset of biomarkers from
the 21. This information is proprietary and a patent application was filed. Patterns of up and down regulation
of biomarkers were similar to our previous study [11].
The median concentration in LC patients compared to
healthy non-smokers, asthma sufferers, and smokers was
more than 200% higher in SAA (771%), MMP-9 (743%),
IL-8 (535%), CXCL9/MIG (482%), TNFRI (406%), Gro
(331%), MPO (300%), Rantes (274%), Resistin (271%),
TNFRII (266), and MIF (219%). IL-2 and IL-7 showed
greater than a 50% reduction in signal (Table 5).
Validation set performance

A novel blinded sample set of 228 (N = 456) subjects
were processed in duplicate using the LCDT1. Of 228
subjects, 55 were Stage I NSCLC samples (Table 2). Our
proprietary algorithm accurately detected 49 of the 55
Stage I LC samples (Fig. 1). There were 6 positive
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Table 3 Results of Algorithm Models. Results of Optimized Algorithm Models (Training Set)
Biomarker

Algorithm 33

Algorithm 21

LCDT1 Algorithm

SE (95% CI)

92.8% (87.9, 96.1%)

97.4% (92.0, 99.5%)

92.4% (89.2, 94.3%)

SP (95% CI)

97.2% (95.5, 98.8%)

98.3% (95.4, 99.5%)

96.9% (95.2, 98.0%)

The LCDT1 algorithm was developed with slight modifications using a smaller subset of biomarkers from the 21. This information is proprietary and a patent
application was filed

samples that were not detected and 4 negative LC samples that showed up as positive. The 4 samples that were
false positives consisted of 3 breast cancers and 1 asthma
sufferer (Supplementary Table 1). We were unable to
follow-up with the patients to confirm if the breast cancer had metastasized into the lungs [27] or whether the
asthma diagnosis was erroneously reached for an individual actually suffering of LC [28].
Algorithm 33 and the LCDT1 exhibit a similar accuracy rate of 95.6%, sensitivity of 89.1%, and a specificity
of 97.7% in the validation test (Table 4). When only
NSCLC cancers were analyzed, the specificity of both algorithms improved to 99.1%. This validation shows that
the results are comparable using the 33 markers (from
the previous study) versus the 21 or the LCDT1 markers
(Table 4). Additional biomarkers were unnecessary to
achieve the same clinical performance.
ROC curves and P-values

The Area under the ROC Curve (AUC) is the probability
that an observation with a higher probability of being
positive is positive. In our model, a ‘positive’ means that
the model predicts that the subject has NSCLC. Although the discriminatory power, using AUC, for each
individual biomarker was examined, it was not the determining factor in our selection process. The ROC/AUC
for Algorithm 33, Algorithm 21, and the LCDT1 are
0.965, 0.960, and 0.966, respectively (Fig. 2a). When only
NSCLC cancers were analyzed, the AUC for each algorithm improved by 0.01 (Fig. 2b). Once more, the Pvalues (p < 0.05) imply that several biomarkers are able
to discriminate NSCLC from other pathologies to a

Fig. 1 Validation Test Result

degree (Table 5). These results (e.g., patterns, ROC/
AUC, performance) provide a strong foundation for developing a clinical diagnostic test for NSCLC.

Discussion
Protein biomarkers have been extensively examined for
diagnostic, prognostic, and therapeutic assessment of
diseases and its treatments. Yet, many lab-developed assays never fully mature to penetrate the clinical setting
[29]. Apart from the regulatory hurdles, there are many
factors, such as sample collection, reagent manufacturing, and the acquisition of data, that may cause variability of end-results, which affects robustness and
consistency, ~a requisite of any biological test used for
clinical utility [30, 31]. Reducing the number of biomarkers was an important component of the present
study as decreases complexity and the number of interactions between the antibodies, simplifies reagent production, and is more cost-effective [32].
In narrowing our list, the biological justification for
the selection of biomarkers was critical in avoiding numerical quirks that may mask the true driver of a
physiological process [11]. To elaborate, the statistical
model in the previous study was a Random Forest (RF)
model. When an RF model is fit, a measure of the variable’s importance is calculated. In this case, the variables
are the biomarkers. The variable’s importance is defined
as how well, on average, the biomarker increases the distinction of groups in the model (in our case NSCLC and
not-NSCLC). Here, the Node impurity (how well the
trees partition the data at each step in the algorithm) is
measured using the Gini index [33].

Goebel et al. BMC Cancer

(2020) 20:137

Page 6 of 11

Table 4 Blind Test Performance for the 33, 21, and LCDT1 Algorithm (Validation Set)
Model
Statistics

Algorithm 33

Algorithm 21

LCDT1 Algorithm

Accuracy

95.6% (92.4, 97.7%)

94.3% (90.7, 96.8%)

95.6% (92.4, 97.7%)

Sensitivity

89.1% (78.9, 95.3%)

89.1% (78.9, 95.3%)

89.1% (78.9, 95.3%)

Specificity

97.7% (94.6, 99.2%)

96.0% (92.2–98.2%)

97.7% (94.6, 99.2%)

Positive Predictive Value (PPV)

92.5% (83.0, 97.4%)

87.5% (77.0, 94.2%)

92.5% (83.0, 97.4%)

Negative Predictive Value (NPV)

96.6% (93.1, 98.6%)

96.5% (93.0, 98.5%)

96.6% (93.1, 98.6%)

NSCLC Prevalence

24.1%

24.1%

24.1%

True Positive (TP)

49

44

49

True Negative (TN)

169

166

169

False Positive (FP)

4

6

4

False Negative (FN)

6

7

6

All entries show the statistical (95% CI). *Other cancer types were included in the analysis. Each subject consisted of two replicates (N = 2) or two data points
processed by the algorithm. If one data point was positive, then the subject was considered positive for LC. Table was generated using R Version 3.4.4

Due to the naturally occurring relationships between
the biomarkers examined, depending on variable’s importance as the sole factor in determining if a biomarker
should stay in the smaller set of biomarkers to develop
the new model, is not viable. If any two biomarkers are
highly correlated, then the ‘importance’ of one biomarker is masked by the other biomarker. This is because both biomarkers would provide the same
information to the model thereby making the excluded
biomarker redundant. Therefore the ‘redundant’ biomarker, seeming insignificant, could have served as a
substitute for the included biomarker [34].
However, if the two biomarkers are statistically correlated, but only one is biologically related to the disease,
we may not be able to determine which biomarker is
truly more important to the underlying biological mechanisms. Thus, biological relevance and patterns weighed
heavily.
Many of the markers in our set have been studied for
decades and have been shown to have potential for diagnosing LC [35–39]. In our studies, certain biomarkers
were elevated at higher levels or depressed depending on
whether we were looking at early stage (I-II) or late stage
(III-IV) NSCLC patients, e.g., the upregulation of CEA
and CYFRA-21-1 (common cancer markers widely studied) [36] were not as prominent in early stage NSCLC.
The occurrence of a lower expressed CYFRA in the early
stages of NSCLC has been indicated by Guergova-Kuras
M, et al. [37] using monoclonal antibodies to detect
early stage NSCLC. This phenomenon of varying marker
levels at different stages of NSCLC is not surprising as
protein abundance reflects current physiological state of
the disease.
Examples of the markers that were elevated in stage III NSCLC were IL-8, MMP-9, and SAA. The synergistic
regulation and pathways of these markers correlates with

previous scientific findings: For example, IL-8 is a multifunctional chemokine that induces chemotaxis and
phagocytosis, promotes angiogenesis, and aids in maintenance of mesenchymal features in carcinoma cells [40,
41]. Robust upregulation of CXCL8 (aka IL-8) has been
observed in erlotinib-resistant cell lines [41] which also
makes it a cancer therapy target. A study by Liu et al.
using 141 NSCLC patients indicated that IL-8 may have
up-regulated MMP-9 in lymph node metastasis of
NSCLC patients [38].
MMP-9 is a widely studied protease that cleaves extracellular matrix (ECM) proteins to regulate ECM remodeling [42]. MMP-9 is involved in basement membrane
degradation that furthers tumor invasion and metastases
[42]. Past studies showed that MMP-9 s are highly elevated in LC patients, especially stage III-IV [43, 44]. We
also observed a correlation between IL-8 and MMP-9
levels in LC patients.
SAA is an apolipoprotein that is secreted during acute
phase inflammation and is a known LC biomarker. Sung
et al. measured 180 healthy and 170 lung adenocarcinoma plasma or serum samples and found a 14-fold increase of SAA levels in the LC patient [45]. Another by
Biaoxue, R. et al. indicated that SAA alone could detect
LC with 0.59 sensitivity and 0.92 specificity [39]. We
measured a six-fold increase in SAA levels at all stages
of NSCLC compared to healthy controls.
Proteins such as IL-8, MMP-9, and SAA are involved
in physiological inflammatory processes. Some of these
proteins are highly expressed in specific cancers, while
others are inhibited. Independently, each protein has the
ability of discriminating healthy from disease patients.
When LC biomarkers are multiplexed and combined
with an algorithm and additional demographic data, its
diagnostic capability increases and could serve as a
powerful clinical tool.
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Fig. 2 ROC/AUC Curves. a. ROC/AUC Curves with other cancers types included. b. ROC/AUC Curves with only NSCLC cancers. Figures were
generated using R version 3.4.4

Using biomarkers for diagnosing diseases requires
constant revalidation to ensure that it remains applicable
to the intended population. Like any method, biomarkers have limitations as they are affected by sample

origin, ethnicity, gender, environmental and carcinogenic
exposure, and reagent and platform variations. Strict
quality assurance and processes from the bench (e.g., developing reagents) to the clinic (e.g., collecting samples)
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Table 5 Median Biomarker Concentrations and P-Value Using the Training Set
Biomarker

NSCLC Median [Q1-Q3], pg/mL

Asthma, Smokers, Non-Smokers Median [Q1-Q3], pg/mL

P-Value

CA125

26.4
[13.7–41.7]

13.6
[6.9–36.7]

0.073

CEA

2884.4
[1815.9–5573.8]

2115.3
[1194.8–3242.2]

0.003

CXCL9-MIG

4378.2
[2604.0–6844.5]

908.0
[539.0–1965.8]

< 0.001

CYFRA-21-1

5354.8
[3429.5–8090.4]

5088.3
[2939.9–9770.1]

0.026

GRO

2890.0[2076.9–4178.0]

874.4
[507.5–1790.2]

< 0.001

HGF

869.4
[643.9–1647.1]

476.3
[271.9–1177.1]

0.006

IL-10

22.8
[11.7–38.2]

23.8
[14.0–45.8]

0.525

IL-12p70

21.1
[15.5–27.0]

19.9
[16.5–127.4]

0.082

IL-16

693.6
[345.1–1458.7]

717.5
[298.8–1469.4]

0.902

IL-2

11.5
[10.9–16.6]

33.8
[19.7–52.1]

0.005

IL-4

41.7
[25.3–51.6]

33.3
[22.5–50.3]

0.902

IL-5

17.9
[15.7–23.5]

28.7
[12.8–46.8]

0.188

IL-7

10.6
[10.6–10.6]

34.9
[18.9–61.1]

NA

IL-8

126.3
[44.5–323.8]

23.6
[15.9–42.3]

< 0.001

IL-9

11.9
[11.0–20.7]

22.3
[15.2–42.6]

0.016

Leptin

30,408.0
[16,682.6–45,886.3]

22,190.7
[8684.4–54,863.7]

0.224

LIF

45.5
[30.5–79.3]

39.6
[27.1–82.3]

0.511

MCP-1

530.2
[391.363–721.512]

372.8
[279.7–462.0]

< 0.001

MIF

865.6
[453.6–1501.3]

395.0
[196.7–1274.8]

0.752

MMP-7

1978.3
[1184.2–3190.33]

3585.2
[2671.9–5080.6]

< 0.001

MMP-9

93,587.2
[62,827.2–124,300.6]

12,593.8
[8856.8–19,799.6]

< 0.001

MPO

353,987.8
[246,376.2–616,739.2]

117,658.8
[69,768.5–212,726.3]

< 0.001

NSE

7273.5
[3852.3–10,487.8]

6576.1
[3806.6–46,981.4]

< 0.001

PDGF AB/BB

25,169.6
[21,611.8–30,055.0]

41,800.6
[26,115.3–53,016.0]

< 0.001

RANTES

105,356.2
[79,497.9–155,040.2]

38,458.4
[23,423.8–112,641.5]

0.003

Resistin

35,145.6
[25,185.8–53,466.7]

12,966.2
[9521.2–17,533.1]

< 0.001

SAA

6.55e7
[2.52e7–1.2e8]

8.5e6
[4.175e6–1.9825e7]

< 0.001
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Table 5 Median Biomarker Concentrations and P-Value Using the Training Set (Continued)
Biomarker

NSCLC Median [Q1-Q3], pg/mL

Asthma, Smokers, Non-Smokers Median [Q1-Q3], pg/mL

P-Value

sCD40L

381.8
[155.9–752.5]

219.9
[110.285–628.7]

0.018

sEGFR

654.9
[544.0–1175.5]

936.5
[543.2–1943.2]

< 0.001

sFasL

229.8
[78.2–498.2]

263.7
[135.9–573.4]

0.03

sICAM-1

150,304.6
[123,699.9–187,843.8]

145,329.4
[117,164.7–182,796.7]

0.519

sTNFRII

15,477.5
[11,712.9–20,103.6]

5818.1
[4574.8–7295.3]

< 0.001

TNFRI

2514.8
[1748.7–3743.5]

619.5
[413.9–860.2]

< 0.001

Table was generated using R Version 3.4.4

to the acquisition of the end result (e.g., data cleaning
and processing) are imperative. Furthermore, statistical
and machine learning algorithms also need to be tested
for bias and refined as new data are collected.
Despite, these limitations, biomarkers in conjunction
with machine learning methods serve as an important
component in fighting cancer as they provide benefits.
Such advantages include a means of a simple, noninvasive method in detecting cancer; acquiring prognostic information, and assessment of the efficacy of therapeutic methods.

Conclusions
We aimed to develop an accurate test that was specific
to early stage NSCLC. A multi-cancer test, though remarkable, could increase patient anxiety and fiscal expense due to additional (possibly unnecessary) follow-up
procedures. These concerns are mirrored in medical
practitioners’ reluctance to order full body imaging in
asymptomatic patients [46].
This study shows that we were able to successfully reduce the number of biomarkers from 33 to 21, while
maintaining a high performance in detecting early stage
NSCLC. The LCDT1 is 97.7% specific for Stage I
NSCLC even when other cancer types were present. An
estimated 9 out of 10 (89.1% sensitive) early stage LC
patients would be detected by the LCDT1. The LCDT1
is 95.6% accurate.
As a diagnostic test, physicians prefer tests with high
sensitivity and sacrifice specificity. The argument is that
not detecting “a” cancer is more detrimental than a false
negative. A highly sensitive diagnostic test is important
where the test is used to identify a serious but treatable
disease; and a highly specific test avoids further subjection of the patient to unnecessary follow-up medical
procedures. In the case of LC, current diagnostic
methods (i.e., CT, PET) have high sensitivity but low
specificity. If patients who are suspected to have a lung

nodule on a CT are given a second test with a low (or
high) sensitivity and high specificity, then nearly all of
the false positives could be identified as disease free.
Our clinical goal is to decrease risks and unnecessary
procedures to patients without delaying curative treatment [47] and increase access to communities with social and economic barriers. The LCDT1 is a simple
blood test with great potential for clinical applications in
detecting Stage I NSCLC. When used with gold standards such as the CT/PET scans in conjunction with algorithms and improved PN guidelines, could mean a
significant reduction in the number of false negatives
and an increase in early stage detection.
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